Mylan NV (MYL.OQ)
40.69USD
19 Apr 2018
$-0.05 (-0.12%)
$40.74
$40.82
$41.20
$40.54
139,928
1,792,945
$47.81
$29.44
About
Overall
| Beta: | 1.33 |
| Market Cap(Mil.): | $20,972.21 |
| Shares Outstanding(Mil.): | 514.78 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MYL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.50 | 30.61 | 33.50 |
| EPS (TTM): | 1.54 | -- | -- |
| ROI: | 2.79 | 13.57 | 13.17 |
| ROE: | 6.75 | 15.25 | 14.98 |
EpiPen shortages seen in Canada, UK but U.S. supply intact
NEW YORK Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.
EpiPen shortages seen in Canada, UK but U.S. supply intact
NEW YORK, April 13 Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.
Deals of the day-Mergers and acquisitions
April 13 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
Mylan seeks deal for German Merck's consumer products unit: sources
FRANKFURT/NEW YORK Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.
UPDATE 2-Mylan seeks deal for German Merck's consumer products unit -sources
FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.
Mylan seeks deal for German Merck’s consumer products unit -sources
FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.
BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam
* MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC
BRIEF-Mylan NV Says Reaffirming 2018 Guidance
* FY2018 EARNINGS PER SHARE VIEW $5.38, REVENUE VIEW $12.44 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU
* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:
BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics
* MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)
Estimates